Intrinsic value of Liminatus Pharma, Inc. Class A Common Stock (LIMN)
Live fair value data for Liminatus Pharma, Inc. Class A Common Stock (LIMN) is currently unavailable. Please check again shortly.
Current Price: $314.00
Valuation: Overvalued
Confidence: 4.0/10
Visual Bar
This intrinsic value is calculated using 5 different models based on projected revenue growth, profit margins, and a standard discount rate.
Is Liminatus Pharma, Inc. Class A Common Stock (LIMN) undervalued or overvalued?
Based on the current model output, Liminatus Pharma, Inc. Class A Common Stock appears to be overvalued with a downside of 3.00%.
Fair value vs market price — Liminatus Pharma, Inc. Class A Common Stock (LIMN)
Unlock premium access to view the live fair value comparison against current market price for LIMN.
Frequently Asked Questions - LIMN
How is LIMN intrinsic value estimated?
We combine revenue growth, discount rate, and terminal growth assumptions to estimate a fair value range for LIMN.
Is LIMN undervalued or overvalued right now?
LIMN is currently shown as overvalued based on the difference between market price and intrinsic value.
How should I use the confidence score?
The confidence score (0 to 10) indicates model certainty from available inputs. Higher values suggest stronger model consistency, not a guarantee of returns.
Related companies — intrinsic value
Peers for LIMN: open their intrinsic value pages.